Ontology highlight
ABSTRACT: Aims
Nocturnal acid breakthrough has been considered an unmet need of proton-pump inhibitors. Tegoprazan, a novel potassium-competitive acid blocker, is expected to show improved properties for this unmet need. This study was aimed to compare night-time acid suppression by tegoprazan with that by vonoprazan or esomeprazole, and to explore the effect of CYP2C19 phenotypes on acid-suppressive effects.Methods
A randomized, open-label, 3-period, 6-sequence crossover study was conducted. A single oral dose of tegoprazan 50 mg, vonoprazan 20 mg or esomeprazole 40 mg was administered at night in each period. Continuous intragastric pH was monitored at baseline and after each dosing.Results
Sixteen healthy subjects (6 CYP2C19 extensive metabolizers, 5 intermediate metaboliz
SUBMITTER: Yang E
PROVIDER: S-EPMC9305887 | biostudies-literature | 2022 Jul
REPOSITORIES: biostudies-literature